HuidaGene Therapeutics
辉大（上海）生物科技有限公司
HuidaGene Therapeutics, founded in 2018 and headquartered in Shanghai with a site in New Jersey, is a clinical-stage gene-editing company that discovers and engineers CRISPR/Cas tools (Cas12 DNA editing, Cas13 RNA editing) and develops AAV-delivered therapies for inherited diseases in ophthalmology, neurology, myology and otology.
About
HuidaGene Therapeutics, founded in 2018 and headquartered in Shanghai with a site in New Jersey, is a clinical-stage gene-editing company that discovers and engineers CRISPR/Cas tools (Cas12 DNA editing, Cas13 RNA editing) and develops AAV-delivered therapies for inherited diseases in ophthalmology, neurology, myology and otology. Its HG-PRECISE platform uses machine learning on metagenomic data to discover novel Cas proteins.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- HuidaGene Therapeutics
HuidaGene Therapeutics, founded in 2018 and headquartered in Shanghai with a site in New Jersey, is a clinical-stage gene-editing company that discovers and engineers CRISPR/Cas tools (Cas12 DNA editing, Cas13 RNA editing) and develops AAV-delivered therapies for inherited diseases in ophthalmology, neurology, myology and otology. Its HG-PRECISE platform uses machine learning on metagenomic data to discover novel Cas proteins.
—
United States
BusinessLatest roundTotal raisedDate- Acrobat Genomics
Acrobat Genomics is a Stanford drug-discovery spinout and public benefit corporation at MBC BioLabs in San Carlos, CA. Its AcrobaTx Engine pairs AI-proposed gene-editor, inhibitor and protein designs with high-throughput functional screening in human cells in a closed loop. It is a prime contractor on DARPA's RIDDL program, NIH-funded, and an Illumina Accelerator 2022 company.
— - LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M - Odyssey Therapeutics
Small-molecule and protein therapeutics developed with AI and machine learning
Series C · $101M · 2023-12
$101M
China
BusinessLatest roundTotal raisedDate- NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
— - Convergen
TRIM21-based TrimTAC targeted protein degradation platform for therapies clearing pathological protein aggregates; pipeline focused on neurodegenerative and autoimmune diseases
Seed · $25M · 2026-08
$25M - LigIT
AI-native peptide drug design platform and in-house pipeline
Seed · 2026-10
—
Europe
BusinessLatest roundTotal raisedDate- WhiteLab Genomics
ALFRED platform for AI design and optimization of gene therapy delivery vectors (AAV, lipid nanoparticles) and genetic payloads
Series B · 2026-10
— - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.